ENTtoday
  • Home
  • COVID-19
  • Practice Focus
    • Allergy
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
  • Departments
    • Issue Archive
    • TRIO Best Practices
      • Allergy
      • Facial Plastic/Reconstructive
      • Head and Neck
      • Laryngology
      • Otology/Neurotology
      • Pediatric
      • Rhinology
      • Sleep Medicine
    • Career Development
    • Case of the Month
    • Everyday Ethics
    • Health Policy
    • Legal Matters
    • Letter From the Editor
    • Medical Education
    • Online Exclusives
    • Practice Management
    • Resident Focus
    • Rx: Wellness
    • Special Reports
    • Tech Talk
    • Viewpoint
    • What’s Your O.R. Playlist?
  • Literature Reviews
    • Allergy
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
  • Events
    • Featured Events
    • TRIO Meetings
  • Contact Us
    • About Us
    • Editorial Board
    • Triological Society
    • Advertising Staff
    • Subscribe
  • Advertise
    • Place an Ad
    • Classifieds
    • Rate Card
  • Search

Regular NSAID Use May Improve Survival in Some with Head and Neck Cancer

by Amy E. Hamker • August 12, 2019

  • Tweet
  • Email
Print-Friendly Version

You Might Also Like

  • High-Volume Hospitals, Surgeons Better Predictors of Overall Survival in Head, Neck Cancer
  • Survival for Advanced Head, Neck Cancer Improvements May Be Related to PET
  • Depression Affects Two-Year Survival Rates in Head and Neck Cancer Patients
  • Younger Patients with Oral Tongue Squamous Cell Carcinoma Have Better Survival Rates
Explore This Issue
August 2019

Comment: This study shows that there is a type of squamous cell carcinoma with a specific mutation that had improved survival if NSAIDs were given, likely due to suppression of inflammation.—Andy Murr, MD

What is the impact of nonsteroidal anti-inflammatory drugs (NSAIDs) on disease-specific survival (DSS) and overall survival (OS) in patients with PIK3CA-characterized head and neck squamous cell carcinoma (HNSCC), and what mechanism is involved?

Bottom Line
Regular NSAID use likely confers a statistically and clinically significant advantage in DSS and OS in patients with PIK3CA-altered HNSCC.

Background: Regular use of aspirin has been found to be protective against HNSCC development, but there have been inconsistent findings regarding the potential survival benefit of NSAIDs. Activating mutations in PIK3CA, the gene encoding p110α, the catalytic subunit of phosphoinositide-(3)-kinase α (PI3Kα), are common in HNSCC, with 35% of tumors harboring PIK3CA mutation or amplification.

Study design: Electronic medical record review of a cohort of 266 PIK3CA-characterized HNSCC patients, followed by in vivo mouse modeling.

Setting: Department of Otolaryngology, University of Pittsburgh School of Medicine, Penn.

Synopsis: Regular NSAID use was identified in 33% of patients with PIK3CA-altered tumors and 39% of those with WT cells, unamplified PIK3CA. DSS among WT, unamplified PIK3CA patients was unaffected by regular NSAID use, but regular NSAID use was strongly associated with improved DSS for MT and/or amplified PIK3CA patients. Among patients with altered PIK3CA, regular NSAID users had an absolute five-year DSS advantage of 47%. Among patients with altered PIK3CA, regular NSAID users had an absolute five-year OS advantage of 33%. Findings were tested using in vivo HNSCC models. Mice harboring six distinct patient-derived xenografts (PDXs) endogenously expressing either MT or WT PIK3CA were treated with saline or the NSAIDs sulindac, celecoxib, or aspirin followed by assessment of tumor growth. Sulindac, celecoxib, or aspirin treatment reduced the growth rates of MT PIK3CA tumors compared with vehicle-treated tumors, but not PIK3CA WT tumors. Sulindac treatment led to significantly greater reduction in prostaglandin E2 (PGE2) secretion in cells overexpressing MT versus WT PIK3CA. Limitations included NSAID use determination defined through prescription refill records and patient self-reporting, cohort size, particularly among subgroups, and inconsistencies in the type, timing, and dosages of NSAID therapy.

Citation: Hedberg ML, Peyser ND, Bauman JE, et al. Use of nonsteroidal anti-inflammatory drugs predicts improved patient survival for PIK3CA-altered head and neck cancer. J Exp Med. 2019;216:419–427.

Filed Under: Head and Neck, Literature Reviews Tagged With: head and neck cancer, NSAIDIssue: August 2019

You Might Also Like:

  • High-Volume Hospitals, Surgeons Better Predictors of Overall Survival in Head, Neck Cancer
  • Survival for Advanced Head, Neck Cancer Improvements May Be Related to PET
  • Depression Affects Two-Year Survival Rates in Head and Neck Cancer Patients
  • Younger Patients with Oral Tongue Squamous Cell Carcinoma Have Better Survival Rates

The Triological SocietyENTtoday is a publication of The Triological Society.

The Laryngoscope
Ensure you have all the latest research at your fingertips; Subscribe to The Laryngoscope today!

Laryngoscope Investigative Otolaryngology
Open access journal in otolaryngology – head and neck surgery is currently accepting submissions.

Classifieds

View the classified ads »

TRIO Best Practices

View the TRIO Best Practices »

Top Articles for Residents

  • Do Training Programs Give Otolaryngology Residents the Necessary Tools to Do Productive Research?
  • Why More MDs, Medical Residents Are Choosing to Pursue Additional Academic Degrees
  • What Physicians Need to Know about Investing Before Hiring a Financial Advisor
  • Tips to Help You Regain Your Sense of Self
  • Should USMLE Step 1 Change from Numeric Score to Pass/Fail?
  • Popular this Week
  • Most Popular
  • Most Recent
    • The Dramatic Rise in Tongue Tie and Lip Tie Treatment
    • Vertigo in the Elderly: What Does It Mean?
    • Experts Delve into Treatment Options for Laryngopharyngeal Reflux
    • Weaning Patients Off of PPIs
    • Some Laryngopharyngeal Reflux Resists PPI Treatment
    • Vertigo in the Elderly: What Does It Mean?
    • New Developments in the Management of Eustachian Tube Dysfunction
    • Some Laryngopharyngeal Reflux Resists PPI Treatment
    • Eustachian Tuboplasty: A Potential New Option for Chronic Tube Dysfunction and Patulous Disease
    • The Dramatic Rise in Tongue Tie and Lip Tie Treatment
    • Did You Receive COVID-19 Relief? Here Are Reporting Considerations for 2021
    • Otolaryngology Experts Share Best Practices in Five Areas
    • How Climate Change May Be Affecting Sleep Patterns for Adults and Children
    • Laryngologists Discuss Tough Tracheostomy Choices During COVID-19 Era
    • Head and Neck Cancer: Experts Discuss How to Improve Surgery Quality and Value

Polls

Did you receive funding from the CARES Act or Paycheck Protection Program?

View Results

Loading ... Loading ...
  • Polls Archive
  • Home
  • Contact Us
  • Advertise
  • Privacy Policy
  • Terms of Use

Visit: The Triological Society • The Laryngoscope • Laryngoscope Investigative Otolaryngology

Wiley
© 2021 The Triological Society. All Rights Reserved.
ISSN 1559-4939

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.